Biodexa Pharmaceuticals (BDRX) Competitors $3.99 -0.01 (-0.25%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends BDRX vs. GLMD, SLRX, ATNF, VRPX, PBM, CWBR, ONCT, GRTX, PBLA, and SXTCShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Galmed Pharmaceuticals (GLMD), Salarius Pharmaceuticals (SLRX), 180 Life Sciences (ATNF), Virpax Pharmaceuticals (VRPX), Psyence Biomedical (PBM), CohBar (CWBR), Oncternal Therapeutics (ONCT), Galera Therapeutics (GRTX), Panbela Therapeutics (PBLA), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Galmed Pharmaceuticals Salarius Pharmaceuticals 180 Life Sciences Virpax Pharmaceuticals Psyence Biomedical CohBar Oncternal Therapeutics Galera Therapeutics Panbela Therapeutics China SXT Pharmaceuticals Biodexa Pharmaceuticals (NASDAQ:BDRX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Which has preferable earnings & valuation, BDRX or GLMD? Galmed Pharmaceuticals has lower revenue, but higher earnings than Biodexa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$83K5.72-$7.66MN/AN/AGalmed PharmaceuticalsN/AN/A-$6.91M-$16.66-0.18 Is BDRX or GLMD more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Galmed Pharmaceuticals N/A -28.75%-24.98% Does the MarketBeat Community believe in BDRX or GLMD? Galmed Pharmaceuticals received 441 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 63.69% of users gave Galmed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesGalmed PharmaceuticalsOutperform Votes44263.69% Underperform Votes25236.31% Do institutionals and insiders hold more shares of BDRX or GLMD? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer BDRX or GLMD? In the previous week, Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled Galmed Pharmaceuticals'average media sentiment score. Company Overall Sentiment Biodexa Pharmaceuticals Neutral Galmed Pharmaceuticals Neutral Do analysts prefer BDRX or GLMD? Biodexa Pharmaceuticals presently has a consensus target price of $200.00, suggesting a potential upside of 4,912.53%. Given Biodexa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Biodexa Pharmaceuticals is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Galmed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, BDRX or GLMD? Biodexa Pharmaceuticals has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. SummaryBiodexa Pharmaceuticals beats Galmed Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad Stansberry Research$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.Click here to see his new research now. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$475,000.00$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.20Price / Sales5.72196.061,117.09117.05Price / CashN/A57.1643.1037.85Price / Book0.095.094.784.78Net Income-$7.66M$151.83M$120.31M$225.60M7 Day Performance-5.00%-2.14%-1.92%-1.23%1 Month Performance-16.00%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals1.5809 of 5 stars$3.99-0.3%$200.00+4,912.5%N/A$475,000.00$83,000.000.0021GLMDGalmed Pharmaceuticals0.4246 of 5 stars$3.10+4.4%N/A-31.3%$1.98MN/A-0.1820Gap UpSLRXSalarius PharmaceuticalsN/A$1.37-6.8%N/A-67.0%$1.97M$1.84M-0.1820Positive NewsATNF180 Life SciencesN/A$1.84-4.7%N/A-43.3%$1.89MN/A0.007News CoverageGap UpVRPXVirpax Pharmaceuticals1.0729 of 5 stars$0.36-10.0%$3.00+733.1%-90.8%$1.76MN/A0.007PBMPsyence BiomedicalN/A$1.90+2.7%N/AN/A$1.60MN/A0.00N/ANews CoveragePositive NewsGap UpCWBRCohBarN/A$0.54-0.1%N/A-28.0%$1.57MN/A0.0010High Trading VolumeONCTOncternal Therapeutics2.4371 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530Analyst ForecastGRTXGalera TherapeuticsN/A$0.03-5.0%N/A-76.3%$1.55MN/A-0.0530Gap DownPBLAPanbela TherapeuticsN/A$0.31-2.2%$500.00+158,933.1%-98.1%$1.53MN/A0.007Gap DownSXTCChina SXT Pharmaceuticals0.1725 of 5 stars$0.38-2.5%N/A-82.5%$1.52M$1.93M0.0090Positive NewsGap Up Related Companies and Tools Related Companies Galmed Pharmaceuticals Competitors Salarius Pharmaceuticals Competitors 180 Life Sciences Competitors Virpax Pharmaceuticals Competitors Psyence Biomedical Competitors CohBar Competitors Oncternal Therapeutics Competitors Galera Therapeutics Competitors Panbela Therapeutics Competitors China SXT Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDRX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
